Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Asthma

In brief

The aim of the study is to assess and compare efficacy and safety of BI 54903 at 3 doses twice daily (b.i.d.) and fluticasone propionate hydrofluoroalkane metered dose inhaler (HFA MDI) at a dose of 88 mcg b.i.d and placebo b.i.d. over an 8-week treatment period in asthmatic patients aged 12 to 65 years inadequately controlled on short-acting-beta-agonist (SABA) prn therapy only as demonstrated by a decrease in forced expiratory volume in one second (FEV1) range10 to 25% and an asthma control questionnaire (ACQ-6) equal or greater than 1.5 at time of randomization

Key facts

Study ID

NCT01397162

Run by

Boehringer Ingelheim

People needed

29

Starts

2011-07-21

Expected to finish

2011-12-23

Last updated by the study team

2022-06-23

Who can join

Age: 12 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female patients aged at least 12 to 65 years
• All patients must have a history of asthma diagnosed by a physician for at least three months at the time of enrolment into the trial according to the 2009 Global Initiative for Asthma (GINA) Guidelines. The initial diagnosis of asthma must have been made before the age of 40 years 4 All patients must be on a maintenance treatment with either low-dose inhaled corticosteroid (ICS) plus long-acting-beta -agonist (LABA) or medium-dose ICS without LABA, stable for at least six weeks prior to Visit 1
• 5 All patients must have a pre-bronchodilator FEV1 of not less than 60 to 90% of predicted normal and an asthma control questionnaire (ACQ-6) mean score of less than 1.5 at the pre-screening Visit 1 6 All patients must have an improvement in forced expiratory volume in one second (FEV1) not less than 12 % above baseline and an absolute change of at least 200 mL within 15-30 min after administration of 400 mcg salbutamol/albuterol hydrofluoroalkane metered dose inhaler (HFA MDI) 7 Patients must be never-smokers or ex-smokers with a smoking history of less than 10 pack-years and smoking cessation at least one year prior to screening 9 Patients must be able to use Respimat® inhaler and metered dose inhaler (MDI) correctly 10 Patients must be able to perform all trial-related procedures including technically acceptable pulmonary function tests and electronic peak expiratory flow (PEF) measurements, and must be able to maintain records during the study period as required in the protocol

You may not qualify if…

• Patients with significant pulmonary disease other than asthma or other significant medical conditions (as determined by medical history, examination and clinical investigations at screening)
• Patients with a clinically relevant, abnormal screening haematology and/or blood chemistry finding
• Patients with a history of upper or lower respiratory tract infection (URTI/LRTI) in the past four weeks prior to the pre-screening Visit 1, and during pre-screening and run-in periods
• Patients with any exacerbation of their underlying asthma during the eight weeks prior to the pre-screening Visit 1
• Patients with active allergic rhinitis requiring treatment with systemic corticosteroids
• Any of the following criteria are met during the pre-screening / run-in period (Visits 1 - 6):in clinic pre-bronchodilator forced expiratory volume in one second (FEV1 %) predicted less than 40%; more than 12 puffs rescue salbutamol/albuterol HFA MDI per day for > 2 consecutive days;exacerbation of asthma
• Patients with a history of pneumonectomy or who are planning to undergo thoracotomy for any reason
• Patients who are currently in a pulmonary rehabilitation program or have completed a pulmonary rehabilitation program in the six weeks prior to the first screening visit 1
• Patients with two or more hospitalizations for asthma within the previous 12 months
• Patients with a recent history of myocardial infarction during the last twelve months or known coronary heart disease that requires treatment
• Patients with a history of hospitalisation due to heart failure in the past twelve months
• Patients with myocarditis or any unstable or life-threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy within the past year
• Patients with significant alcohol or drug abuse in the opinion of the investigator within the past two years
• Patients with rheumatoid arthritis or other systemic diseases that require immune system modulating treatment
• Patients suffering from narrow angle glaucoma with a history of glaucoma, increased intraocular pressure, and/or cataracts
• Pregnant or nursing women
• Women of childbearing potential not using a highly effective method of birth control
• Patients who have been treated with anti-Immunoglobin-E-antibodies (e.g. omalizumab, Xolair®) or other immune system modulating antibodies such as tumor necrosis factor-alpha blockers within six months prior to Visit 1
• Patients who have been treated with the following drugs during the past four weeks prior to Visit 1 or are foreseen to need this during the study:Non-selective beta-blockers (topical cardio-selective beta-blocker eye medications for non-narrow angle glaucoma are allowed; Oral or other systemic corticosteroids; Oral beta-agonists; Changes in allergen desensitisation therapy in last 6 months; Immune system modulating agents such as methotrexate or cyclosporine; Inhibitors of cytochrome P450 3A4 such as antifungals (e.g. ketoconazole, itraconazole), antibiotics (e.g. erythromycin) or antiretroviral drugs; Patients who have been treated with leukotriene modifiers, chromones or theophylline within two weeks prior to Visit 1; Patients who have been treated with tiotropium within 3 weeks prior to Visit 1

Where it is running

• 1248.5.01047 Boehringer Ingelheim Investigational Site — Fountain Valley, California, United States
• 1248.5.01041 Boehringer Ingelheim Investigational Site — Huntington Beach, California, United States
• 1248.5.01038 Boehringer Ingelheim Investigational Site — Long Beach, California, United States
• 1248.5.01004 Boehringer Ingelheim Investigational Site — Mission Viejo, California, United States
• 1248.5.01028 Boehringer Ingelheim Investigational Site — Palmdale, California, United States
• 1248.5.01014 Boehringer Ingelheim Investigational Site — Rancho Mirage, California, United States
• 1248.5.01044 Boehringer Ingelheim Investigational Site — Stockton, California, United States
• 1248.5.01015 Boehringer Ingelheim Investigational Site — Centennial, Colorado, United States
• 1248.5.01022 Boehringer Ingelheim Investigational Site — Miami, Florida, United States
• 1248.5.01042 Boehringer Ingelheim Investigational Site — Sarasota, Florida, United States
• 1248.5.01051 Boehringer Ingelheim Investigational Site — Columbus, Georgia, United States
• 1248.5.01052 Boehringer Ingelheim Investigational Site — Savannah, Georgia, United States
• 1248.5.01011 Boehringer Ingelheim Investigational Site — Eagle, Idaho, United States
• 1248.5.01055 Boehringer Ingelheim Investigational Site — Oak Lawn, Illinois, United States
• 1248.5.01019 Boehringer Ingelheim Investigational Site — Baltimore, Maryland, United States
• 1248.5.01039 Boehringer Ingelheim Investigational Site — North Dartmouth, Massachusetts, United States
• 1248.5.01037 Boehringer Ingelheim Investigational Site — Ypsilanti, Michigan, United States
• 1248.5.01056 Boehringer Ingelheim Investigational Site — Rolla, Missouri, United States
• 1248.5.01036 Boehringer Ingelheim Investigational Site — Warrensburg, Missouri, United States
• 1248.5.01020 Boehringer Ingelheim Investigational Site — Omaha, Nebraska, United States
• 1248.5.01049 Boehringer Ingelheim Investigational Site — Berlin, New Jersey, United States
• 1248.5.01054 Boehringer Ingelheim Investigational Site — Trenton, New Jersey, United States
• 1248.5.01010 Boehringer Ingelheim Investigational Site — Verona, New Jersey, United States
• 1248.5.01006 Boehringer Ingelheim Investigational Site — Rochester, New York, United States
• 1248.5.01031 Boehringer Ingelheim Investigational Site — High Point, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.